CG Oncology, Inc. Investment Income, Interest
CG Oncology, Inc. (CGON) reported Investment Income, Interest of $7.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-06
- CG Oncology, Inc. investment income, interest for the quarter ending 2026-06-30 was $7.33M, a 0.14% increase year-over-year.
- CG Oncology, Inc. investment income, interest for the quarter ending 2026-03-31 was $6.29M, a 18.83% decline year-over-year.
- CG Oncology, Inc. investment income, interest for the quarter ending 2025-12-31 was $7.44M, a 19.20% increase year-over-year.
- CG Oncology, Inc. investment income, interest for the quarter ending 2025-09-30 was $7.42M, a 5.97% decline year-over-year.
- CG Oncology, Inc. investment income, interest for fiscal 2025 was $29.93M, a 12.42% increase from fiscal 2024.
- CG Oncology, Inc. investment income, interest for fiscal 2024 was $26.62M, a 285.63% increase from fiscal 2023.
- CG Oncology, Inc. investment income, interest for fiscal 2023 was $6.90M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 3 month as first filed | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $7.33M 10-Q · filed 2026-08-06 | $13.62M 10-Q · filed 2026-08-06 | $21.06M derived: sum of 3 quarters · filed 2026-08-06 | $28.48M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $6.29M 10-Q · filed 2026-05-08 | $13.73M derived: sum of 2 quarters · filed 2026-05-08 | $21.15M derived: sum of 3 quarters · filed 2026-05-08 | $28.47M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $7.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $14.87M derived: sum of 2 quarters · filed 2026-02-27 | $22.18M derived: sum of 3 quarters · filed 2026-08-06 | $29.93M 10-K · filed 2026-02-27 | |
| 2025-09-30 | $7.42M 10-Q · filed 2025-11-14 | $14.74M derived: sum of 2 quarters · filed 2026-08-06 | $22.49M 10-Q · filed 2025-11-14 | $28.73M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $7.32M 10-Q · filed 2026-08-06 | $15.07M 10-Q · filed 2026-08-06 | $21.31M derived: sum of 3 quarters · filed 2026-08-06 | $29.20M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $7.75M 10-Q · filed 2026-05-08 | $13.99M derived: sum of 2 quarters · filed 2026-05-08 | $21.88M derived: sum of 3 quarters · filed 2026-05-08 | $28.83M derived: sum of 4 quarters · filed 2026-05-08 | |
| 2024-12-31 | $6.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $14.14M derived: sum of 2 quarters · filed 2026-02-27 | $21.08M derived: sum of 3 quarters · filed 2026-02-27 | $26.62M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $7.89M 10-Q · filed 2025-11-14 | $14.84M derived: sum of 2 quarters · filed 2025-11-14 | $20.38M 10-Q · filed 2025-11-14 | $23.18M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-06-30 | $6.94M 10-Q · filed 2025-08-08 | $12.49M 10-Q · filed 2025-08-08 | $15.29M derived: sum of 3 quarters · filed 2026-02-27 | $17.57M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-03-31 | $5.54M 10-Q · filed 2025-05-13 | $5.55M 10-Q · filed 2024-05-09 | $8.35M derived: sum of 2 quarters · filed 2026-02-27 | $10.63M derived: sum of 3 quarters · filed 2026-02-27 | $11.40M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $5.09M derived: sum of 2 quarters · filed 2026-02-27 | $5.86M derived: sum of 3 quarters · filed 2026-02-27 | $6.90M 10-K · filed 2026-02-27 | |
| 2023-09-30 | $2.28M 10-Q · filed 2024-11-12 | $3.05M derived: sum of 2 quarters · filed 2024-11-12 | $4.10M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $771.00K 10-Q · filed 2024-08-08 | $1.82M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $1.05M 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |